Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial superantigens (SAgs) are a family of exceptionally potent exotoxins secreted by Gram-positive pathogens, most notably Staphylococcus aureus and Streptococcus pyogenes (Source: StatPearls, PMID: 31082117). Unlike conventional antigens that require processing and presentation within the MHC groove, SAgs bind directly to the external surfaces of MHC class II molecules and the Vβ region of the T-cell receptor (Source: Nature Reviews Microbiology, PMID: 21822292). This unconventional binding bypasses the specificity of the adaptive immune system, triggering the simultaneous activation of up to 20% of the total T-cell population. The resulting 'cytokine storm'—characterized by massive systemic levels of TNF-alpha, IL-2, and IFN-gamma—leads to rapid-onset hypotension, multi-organ failure, and potentially death, as seen in toxic shock syndrome (Source: Frontiers in Immunology, PMID: 28360921). Therapeutic approaches focus on neutralizing the toxins with intravenous immunoglobulin (IVIG), suppressing their production with protein-synthesis-inhibiting antibiotics like clindamycin, or utilizing novel peptides to disrupt the SAg-host receptor interface (Source: Clinical Microbiology Reviews, PMID: 11148128).
The primary mechanisms include the passive neutralization of toxins by polyvalent antibodies (IVIG), the suppression of toxin synthesis by inhibiting bacterial translation (clindamycin, linezolid), and the competitive blockade of the costimulatory signal required for SAg-mediated T-cell activation (reltecimod).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial superantigen (SAg) (SAg).